BeiGene’s PD-1 Remains Solid In First Global Pivotal Study

Positive Interim Data In Later-Line NSCLC

 
• By Ian Haydock

Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.

Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.
Another Positive Interim Readout For Tislelizumab • Source: Shutterstock

More from Anticancer

More from Therapy Areas